RSV Vaccine Resource Center

Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms. RSV can also cause more severe infections such as bronchiolitis and pneumonia. The population at highest risk for severe RSV includes infants and young children, especially premature infants and those with chronic/congenital health issues. Older adults with heart or lung disease or weakened immune systems are also at higher risk.

RSV is transmitted through contact with droplets from the nose and throat when an infected person coughs or sneezes. It can also spread through contact with respiratory secretions on bedclothes, doorknobs and similar items and then touching the eyes, nose, or mouth. RSV can remain on hard surfaces for many hours and on soft surfaces for shorter amounts of time. Transmission can occur 1 to 2 days prior to symptoms until about 8 days after showing signs of illness. Some infants and immunocompromised individuals can spread the virus even after symptoms resolve, up to 4 weeks.

In May 2023, the FDA approved two separate vaccines by different manufacturers for RSV. In May 2024, the FDA approved a third vaccine by a third manufacturer for RSV. They are indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus. The Advisory Committee on Immunization Practices recommended that individuals 75 years of age and older may receive a single dose of an RSV vaccine. Individuals 60-74 years of age with risk factors for severe RSV disease should also receive a dose of RSV vaccine. Pregnant people between 32 and 36 weeks gestation should receive a dose of RSV vaccine to protect their newborn from severe RSV illness.

Resource Center

You will find below all of the resources you will need about the RSV vaccine. More will be added as they are published or released.